Neurology

Dementia
In the Lab

Tests used to determine if someone needs dementia evals are riddled with bias, study finds

By Eric Boodman

Exhaust pipe
Health

Exposure to air pollution during pregnancy or early life linked to autism diagnosis

By Karen Weintraub

Brain neurons
Biotech

A pharma veteran best known for biotech reflects on leading a startup, pricing a drug, and investing in politics

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Pill stomach
Biotech

Sick of a daily pill? A Boston biotech wants to make a daily Alzheimer’s drug last for a week — and they’re working on more

By Kate Sheridan

STAT Brain Signals Final GIF
In the Lab

With brain implants, scientists hope to translate paralyzed patients’ thoughts into speech

By Sharon Begley

Alzheimers Association
In the Lab

New prize offers $2 million for finding key to Alzheimer’s in past research

By Sharon Begley

Appendix - Parkinson’s disease
In the Lab

It started as a ‘weird idea,’ but a new study shows the appendix can initiate Parkinson’s

By Sharon Begley

Robert Moir
In the Lab

How an outsider in Alzheimer’s research bucked the prevailing theory — and clawed for validation

By Sharon Begley

Epilepsy Student llustration
First Opinion

Epilepsy, my life-threatening condition, is not your ‘undue burden’

By Kurt Eichenwald

Biotech

Pfizer, Bain launch a startup to focus on nervous system diseases

By Jonathan Saltzman — Boston Globe

Homeopathy vials
Health

Crowdfunding raises millions for unproven — and potentially harmful — treatments

By Megan Thielking

Brain map
Biotech

New chemical eyed in fight vs. Alzheimer’s

By Jonathan Saltzman — Boston Globe

Biotech

New data for Genentech’s MS drug shows benefit of early treatment

By Kate Sheridan

Single white lab mouse
In the Lab

Can building a better research mouse open the black box of Alzheimer’s?

By Kate Sheridan

Ear Hair Cells
In the Lab

After decades of false starts, Harvard team says it’s found the ‘missing link’ in how we hear

By Eric Boodman

ACT UP 1989
Health

As Alzheimer’s drug developers give up on today’s patients, where is the outrage?

By Sharon Begley

Empty pipeline
Pharma

That pathetic Alzheimer’s pipeline? It’s even worse than you think

By Sharon Begley

Special Report

An Appalachian odyssey: Hunting for ALS genes along a sprawling family tree

By Eric Boodman

In the Lab

Drugs aimed at a sliver of Parkinson’s patients may benefit many more than thought — and boost a biotech

By Sharon Begley

First Opinion

Finding new treatments for Parkinson’s and Alzheimer’s shouldn’t be up to pharma alone

By Allan Hugh Cole Jr.

Epidiolex
Pharma

FDA approves country’s first medicine made from marijuana

By Andrew Joseph

HHV-6: Radioactive Isotope
In the Lab

New study supports long-dismissed idea: Herpes viruses could play role in Alzheimer’s

By Sharon Begley

Health

Can this doctor figure out how to stop Alzheimer’s before it starts?

By Joshua Kendall

Dr. Alice Flaherty 02
Heavyweights

It’s not ‘all in your head’: When other doctors give up on patients, a boundary-breaking neurologist treats them

By Eric Boodman

Sarah Benoit 01
Pharmalot

ALS patients losing time and hope as they wait for insurers to cover a pricey new drug

By Ed Silverman

Amgen
Biotech

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

By Damian Garde

Epidiolex
Health

Panel recommends FDA approval of epilepsy drug derived from marijuana

By Andrew Joseph

UT Health Medical School
In the Lab

In a bid to promote stem cell therapies, health officials open a new door for promising contenders

By Andrew Joseph

Pharmalot
Pharmalot

New migraine drugs may give insurers a headache

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy